Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis
| dc.contributor.author | Onile, Olugbenga Samson | |
| dc.contributor.author | Musaigwa, Fungai | |
| dc.contributor.author | Ayawei, Nimibofa | |
| dc.contributor.author | Omoboyede, Victor | |
| dc.contributor.author | Onile, Tolulope Adelonpe | |
| dc.contributor.author | Oghenevovwero, Eyarefe | |
| dc.contributor.author | Aruleba, Raphael Taiwo | |
| dc.date.accessioned | 2024-04-29T10:30:06Z | |
| dc.date.available | 2024-04-29T10:30:06Z | |
| dc.date.issued | 2022-09-22 | |
| dc.date.updated | 2022-10-26T11:08:16Z | |
| dc.description.abstract | Leishmaniasis is a neglected tropical disease caused by parasitic intracellular protozoa of the genus <i>Leishmania</i>. The visceral form of this disease caused by <i>Leishmania donovani</i> continues to constitute a major public health crisis, especially in countries of endemicity. In some cases, it is asymptomatic and comes with acute and chronic clinical outcomes such as weight loss, pancytopenia, hepatosplenomegaly, and death if left untreated. Over the years, the treatment of VL has relied solely on chemotherapeutic agents, but unfortunately, these drugs are now faced with challenges. Despite all efforts, no successful vaccine has been approved for VL. This could be as a result of limited knowledge/understanding of the immune mechanisms necessary to regulate parasite growth. Using a computational approach, this study explored the prospect of harnessing the properties of a disulfide isomerase protein of <i>L. donovani</i> amastigotses to develop a multi-epitope subunit vaccine candidate against the parasite. We designed a 248-amino acid multi-epitope vaccine with a predicted antigenicity probability of 0.897372. Analyses of immunogenicity, allergenicity, and multiple physiochemical parameters indicated that the constructed vaccine candidate was stable, non-allergenic, and immunogenic, making it compatible with humans and hence, a potentially viable and safe vaccine candidate against <i>Leishmania</i> spp. Parasites. | |
| dc.identifier | doi: 10.3390/vaccines10101598 | |
| dc.identifier.apacitation | Onile, O. S., Musaigwa, F., Ayawei, N., Omoboyede, V., Onile, T. A., Oghenevovwero, E., & Aruleba, R. T. (2022). Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis. http://hdl.handle.net/11427/39484 | en_ZA |
| dc.identifier.chicagocitation | Onile, Olugbenga Samson, Fungai Musaigwa, Nimibofa Ayawei, Victor Omoboyede, Tolulope Adelonpe Onile, Eyarefe Oghenevovwero, and Raphael Taiwo Aruleba "Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis." (2022) http://hdl.handle.net/11427/39484 | en_ZA |
| dc.identifier.citation | Vaccines 10 (10): 1598 (2022) | |
| dc.identifier.ris | TY - Journal Article AU - Onile, Olugbenga Samson AU - Musaigwa, Fungai AU - Ayawei, Nimibofa AU - Omoboyede, Victor AU - Onile, Tolulope Adelonpe AU - Oghenevovwero, Eyarefe AU - Aruleba, Raphael Taiwo AB - Leishmaniasis is a neglected tropical disease caused by parasitic intracellular protozoa of the genus <i>Leishmania</i>. The visceral form of this disease caused by <i>Leishmania donovani</i> continues to constitute a major public health crisis, especially in countries of endemicity. In some cases, it is asymptomatic and comes with acute and chronic clinical outcomes such as weight loss, pancytopenia, hepatosplenomegaly, and death if left untreated. Over the years, the treatment of VL has relied solely on chemotherapeutic agents, but unfortunately, these drugs are now faced with challenges. Despite all efforts, no successful vaccine has been approved for VL. This could be as a result of limited knowledge/understanding of the immune mechanisms necessary to regulate parasite growth. Using a computational approach, this study explored the prospect of harnessing the properties of a disulfide isomerase protein of <i>L. donovani</i> amastigotses to develop a multi-epitope subunit vaccine candidate against the parasite. We designed a 248-amino acid multi-epitope vaccine with a predicted antigenicity probability of 0.897372. Analyses of immunogenicity, allergenicity, and multiple physiochemical parameters indicated that the constructed vaccine candidate was stable, non-allergenic, and immunogenic, making it compatible with humans and hence, a potentially viable and safe vaccine candidate against <i>Leishmania</i> spp. Parasites. DA - 2022-09-22 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PY - 2022 T1 - Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis TI - Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis UR - http://hdl.handle.net/11427/39484 ER - | en_ZA |
| dc.identifier.uri | http://hdl.handle.net/11427/39484 | |
| dc.identifier.vancouvercitation | Onile OS, Musaigwa F, Ayawei N, Omoboyede V, Onile TA, Oghenevovwero E, et al. Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis. 2022; http://hdl.handle.net/11427/39484. | en_ZA |
| dc.title | Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis | |
| dc.type | Journal Article |